Skip to main content
. Author manuscript; available in PMC: 2012 Jul 15.
Published in final edited form as: Cancer Res. 2011 May 25;71(14):4758–4768. doi: 10.1158/0008-5472.CAN-10-2527

Figure 1. XL880, XL184, and XL999 effects on tumor vessels.

Figure 1

Fluorescence micrographs compare the vasculature of RIP-Tag2 tumors stained for CD31 immunoreactivity. Ai–ii, vascularity is conspicuously greater after vehicle than after XL880 (60 mg/kg) for 7 days. Aiii, dose-response of tumor vessel regression after XL880 for 7 days. Bi–Biii, no reduction of vascularity at 6 hr after XL880 (40 mg/kg) but conspicuous reductions after 1 day or 14 days. Biv, time-course of reduction in tumor vascularity after XL880. Ci–Cii, reduction in vascularity after XL184 (30 mg/kg) for 7 days. Ciii, dose-response after XL184 for 7 days. Di, smaller reduction in vascularity after XL999 than after XL880 or XL184. Dii, narrow, irregular, or fragmented tumor vessels (arrows) still present after XL880 or XL184 for 7 days. Diii, larger and less tortuous tumor vessels (arrows) remain after XL999 for 7 days. * P < 0.001 vs. vehicle. † P < 0.001 vs. XL880 and XL184. Scale bar: 120 µm (A, B, C); 30 µm (D).